• Charles River Laboratories entered a collaboration with Australia’s Magellan Stem Cells to support development of Magellan’s stem cell therapies.
• Charles River will provide cGMP viral safety testing using next-generation sequencing to support regulatory-ready quality control for cell therapies.
• Magellan is preparing a pivotal Phase III program for Zelestrocel, an allogeneic off-the-shelf osteoarthritis stem cell therapy candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610130800BIZWIRE_USPR_____20261013_BW721648) on October 13, 2026, and is solely responsible for the information contained therein.